Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Rhythm · Phase 2 · Completed · Enrollment 164

NCT04963231

ArmPopulationDoseWeeksEstimandWeight change
Stage 1: Setmelanotide (Open-Label)Obesity or overweightn/r16n/r-3.94% at week 16
Stage 2: Setmelanotide (Double-Blind)Obesity or overweightn/r16n/rn/r
Stage 2: Placebo (Double-Blind)Obesity or overweightn/r16n/rn/r